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Abstract We (JMAAV [Japanese patients with MPO-
ANCA-associated vasculitis] Study Group) performed a
prospective, open-label, multi-center trial to evaluate the
usefulness of severity-based treatment in Japanese patients
with myeloperoxidase-anti-neutrophil cytoplasmic anti-
bodies (MPO-ANCA)-associated vasculitis. Patients with
MPO-ANCA-associated vasculitis received a severity-
based regimen according to the appropriate protocol: low-
dose corticosteroid and, if necessary, cyclophosphamide or
azathioprine in patients with mild form; high-dose corti-
costeroid and cyclophosphamide in those with severe form;
and the severe-form regimen plus plasmapheresis in those
with the most severe form. We followed up the patients for
18 months. The primary end points were the induction of
remission, death, and end-stage renal disease (ESRD).
Fifty-two patients were registered, and 48 patients were
enrolled in this study (mild form, n = 23; severe form,
n = 23; most severe form, n = 2). Among the 47 patients
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DOI 10.1007/s10165-011-0525-5who received the predeﬁned therapies, 42 achieved
remission within 6 months, 5 died, and 1 developed ESRD.
Disease ﬂared up in 8 of the 42 patients with remission
during the 18-month follow-up period. The JMAAV trial is
the ﬁrst prospective trial for MPO-ANCA-associated vas-
culitis to be performed in Japan. The remission and death
rates were comparable to those in several previous clinical
trials performed in western counties. The regimen
employed in this trial was tailor-made based on patients’
disease severity and disease type, and it seems that stan-
dardization can be consistent with treatment choices made
according to severity.
Keywords Anti-neutrophil cytoplasmic antibody 
Microscopic polyangiitis  Prophylaxis  Pulmonary-limited
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Introduction
Among small-vessel vasculitides, microscopic polyangiitis
(MPA), Wegener’s granulomatosis (WG), and allergic
granulomatous angiitis (AGA) are known collectively as
anti-neutrophil cytoplasmic antibodies (ANCA)-associated
vasculitis (AAV) because of the involvement of ANCA as
the common pathogenesis [1]. The major target antigens of
ANCA associated with vasculitis are myeloperoxidase
(MPO) and proteinase 3 (PR3). MPO-ANCA is related to
MPA and AGA, and PR3-ANCA is the marker antibody in
WG [2, 3]. MPO-ANCA-associated vasculitis is more
common in Japan [4], whereas PR3-ANCA-associated
vasculitis is more common in Europe and the United Sta-
ates. Granulomatosis with polyangiitis (GPA) (Wegener’s)
has been proposed as an alternative name for WG [5].
Untreated patients with severe AAV with multi-organ
involvement have a poor prognosis, which can be improved
by combination therapy with cyclophosphamide and high-
dose corticosteroid [6]. Randomized controlled trials
(RCTs) have indicated a rate of AAV remission induction
of approximately 90% in 6 months with the standard reg-
imen [7, 8]. As cyclophosphamide induces severe toxicity,
there have been many attempts to develop less toxic
regimens.
The European CYCAZAREM (cyclophosphamide vs.
azathioprine as remission maintenance therapy for AAV)
RCT compared the effectiveness of cyclophosphamide and
azathioprine in the maintenance of remission [7]. The study
population consisted of 155 patients (WG, n = 95; MPA,
n = 60) who achieved remission after induction therapy
with oral cyclophosphamide plus prednisolone. The
patients were assigned randomly to one of two groups with
continuation of either cyclophosphamide or azathioprine.
The rates of relapse were not signiﬁcantly different
between the two groups at 18-month follow-up. Thus, this
study clearly demonstrated that maintenance of remission
could also be achieved with oral azathioprine.
Another European RCT, NORAM (non-renal vasculitis
alternative treatment with methotrexate), compared meth-
otrexate and cyclophosphamide with regard to remission
induction and maintenance in patients with AAV without
signiﬁcant renal involvement [8]. In this trial, 95 patients
with newly diagnosed AAV (89 with WG and 6 with MPA)
were assigned to receive methotrexate or cyclophospha-
mide. At 6 months, 90 and 94% of patients in the metho-
trexate and cyclophosphamide groups, respectively, had
achieved remission. Among the patients who achieved
remission, the relapse rate at 18 months was signiﬁcantly
higher in the methotrexate group. Thus, methotrexate was
as effective as cyclophosphamide for the induction of
remission in patients with non-renal mild AAV, but was
associated with a signiﬁcantly higher relapse rate.
The two RCTs mentioned above included 250 patients
with AAV, among whom 184 patients (74%) had WG,
presumably related to the epidemiological background.
This is a striking difference from the disease prevalence in
Japan, where MPA and MPO-ANCA-associated vasculitis
are more common [4]. Therefore, caution must be taken in
applying the results of these RCTs to Japanese patients. In
this regard, a prospective study was performed to clarify
the effectiveness of the standard regimen in Japanese
patients with MPO-ANCA-associated vasculitis.
Patients, materials, and methods
Study design
The protocol for a prospective, open-label, multi-center trial
was developed by the investigators of the Research Group
of Intractable Vasculitis, the Research Group of Progressive
Glomerular Disease, and the Research Committee of
Complications and Treatment of Immunological Disorders,
Ministry of Health, Labor, and Welfare (MHLW) of Japan.
The trial was registered as ‘‘Prospective study of the
severity-based treatment protocol for Japanese patients with
MPO-ANCA-associated vasculitis (JMAAV)’’ at the Uni-
versity Hospital Medical Information Network, Clinical
Trials Registry (UMIN-CTR; http://www.umin.ac.jp/ctr/
index-j.htm, registration number ID 000000867). The
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Patients positive for MPO-ANCA, who had newly
diagnosed MPA according to the diagnostic criteria for
MPA of the Research Group of Intractable Vasculitis,
MHLW of Japan [9], were screened for eligibility. ANCA
was tested by enzyme-linked immunosorbent assay
(ELISA) for MPO or PR3. Eligible patients were included
in the study after providing written informed consent, in
accordance with the Declaration of Helsinki.
Exclusion criteria were as follows: (1) age [79 years,
(2) peripheral leukocyte count\4000/mm
3, (3) peripheral
platelet count \120,000/mm
3, (4) coexistence of active
infection, (5) end-stage renal disease (ESRD) requiring
hemodialysis, (6) respiratory failure with PaO2 \60 Torr,
(7) liver cirrhosis, (8) malignancy diagnosed within
5 years, (9) pregnancy, or (10) history of cyclophospha-
mide therapy with a cumulative dose of[10 g.
All patients were stratiﬁed into one of three categories
based on their disease severity and distribution of organ
involvement. (1) Severe form: this form included a gen-
eralized type (MPA with involvement of more than two
organs), a pulmo-renal type (glomerulonephritis plus either
limited pulmonary hemorrhage or extended interstitial
pneumonia), and a rapidly progressive glomerulonephritis
(RPGN) type. (2) Most severe form: this form was deﬁned
as patients with diffuse alveolar hemorrhage, intestinal
perforation, acute pancreatitis, cerebral hemorrhage, or
concurrent anti-glomerular basement membrane antibod-
ies. This form also included patients with the severe form
who were resistant to the severity-based treatment protocol
described below. (3) Mild form: this form included a renal-
limited type (except for RPGN), a pulmonary-limited type
(except for pulmonary hemorrhage), and other mild forms.
Patients were treated according to the predeﬁned protocol
described below.
Severity-based treatment protocol for induction
of remission
To induce remission, patients with the severe form were
treated with a regimen consisting of high-dose prednisolone
(0.6–1.0 mg/kg/day) plus oral cyclophosphamide (0.5–2.0
mg/kg/day). Intravenous methylprednisolone (0.5–1.0 g/day
for 3 days) was also considered in these patients. Instead of
oral administration, the use of intravenous cyclophospha-
mide (0.5–0.75 g/m
2, monthly) was also allowed. In
patients with impaired renal function (serum creatinine level
[1.8 mg/dL) or those older than 60 years, the dose of
cyclophosphamide was reduced to 75–50%. Patients with
the RPGN type were further evaluated depending on their
age, serum creatinine level, C-reactive protein (CRP), and
presence of lung involvement. Details of this scoring system
were described elsewhere [10]. Brieﬂy, the scoring system
employed was as follows. Score 1 included either serum
creatinine C3 and \6 mg/dL, age 60–69 years, or CRP
C2.6 and \10 mg/dL. Score 2 included either serum cre-
atinine C6 mg/dL, age C70 years, or CRP C10 mg/dL, or
the presence of lung involvement. Score 3 included the
induction of hemodialysis. Patients were categorized into
four clinical grades by the sum of the scores. Grades 1, 2, 3,
and 4 are equivalent to the sums of the scores 0–2, 3–5, 6–7,
and 8–9, respectively. The regimen for the patients classi-
ﬁed as grade 1–2 and age C70 years or under hemodialysis
consisted of prednisolone at 0.6–0.8 mg/kg/day. The regi-
men for patients classiﬁed as grade 3–4 and age C70 years
or under hemodialysis consisted of intravenous methyl-
prednisolone (0.5–1.0 g/day for 3 days) followed by
prednisolone at 0.6–0.8 mg/kg/day. The use of oral cyclo-
phosphamide (starting at 25 mg/day) was also allowed
based on the disease activity. The regimen for the patients
classiﬁed as any grade and age \70 years and without
hemodialysis was the same as that for the generalized type
and renal-pulmonary type of the severe form mentioned
above. Cyclophosphamide, however, was not necessarily
used, depending on the renal function.
Patients with the most severe form were treated with
plasmapheresis (2.0–3.0 L/day for 3 days; several sessions)
together with the regimen for the severe form described
above.
Patients with the mild form were treated with oral
prednisolone (0.3–0.6 mg/kg/day). Oral immunosuppres-
sive agents (cyclophosphamide or azathioprine, 0.5–1.0
mg/kg/day or 25–75 mg/day, respectively) were also
allowed.
Treatment protocol for maintenance of remission
and prophylaxis against infection
Patients with any form who had attained remission
received maintenance therapy for an additional year, con-
sisting of prednisolone (5–10 mg/day), and in most cases
oral cyclophosphamide or azathioprine (25–75 mg/day).
Prophylaxis against infection, if necessary, was considered
for each patient, and therefore no systematic regimen for
prophylaxis was predetermined.
Deﬁnitions
Remission was deﬁned as the absence of clinical mani-
festations of active vasculitis and a Birmingham Vasculitis
Activity Score 2003 (BVAS2003) of 0–1 point [11].
Relapses were deﬁned as the recurrence or development of
at least one manifestation of vasculitis. The involvement of
each organ was diagnosed as follows: (a) localized pul-
monary hemorrhage was deﬁned as a hemorrhagic shadow
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eralized interstitial lung ﬁbrosis was deﬁned as a ﬁbrotic
shadow in[30% of the whole lung area on chest X-rays,
but lacking pulmonary failure, with PaO2 \60 Torr.
(b) Patients with RPGN were deﬁned as those with
hematuria, proteinuria, and/or urinary casts who developed
renal failure within several weeks or months. Although not
a necessary sign, increases in serum creatinine level more
than twice in a month may aid in the diagnosis. (c) Cardiac
involvement was deﬁned as the occurrence of fresh myo-
cardial infarction, pericarditis, or myocarditis. (d) Nervous
system involvement was deﬁned as fresh cerebral bleeding
or infarction, mononeuritis multiplex, or organic con-
sciousness disturbance. (e) Gastrointestinal involvement
was deﬁned as melena, pancreatic necrosis, or abnormal
results on liver function tests. (f) Skin involvement was
deﬁned as multiple purpura or skin ulcers. (g) Involvement
of the eyes and ear/nose/throat regions was deﬁned as
scleritis, uveitis, retinitis, optic neuritis, acute otitis media,
acute internal otitis, or hemorrhagic rhinitis.
Evaluation
Study assessments were performed at entry, and at
6 weeks, 12 weeks, and 6 months, then every 3 months for
12 months, and at relapse. Assessments included complete
blood count, measurement of the erythrocyte sedimenta-
tion rate (ESR), CRP, serum creatinine, liver enzymes,
urinalysis, MPO-ANCA, and chest radiography. High-
resolution computed tomography of the lung and pul-
monary function tests such as forced vital capacity (FVC),
forced expiratory volume in 1 s (FEV1), and carbon
monoxide diffusion capacity (DLCO) were performed as
required. BVAS was scored at every visit. The vasculitis
damage index (VDI) [12] was scored at entry and then
once every 6 months for 18 months. The Short-Form 36
functional questionnaire (SF-36) was also assessed at entry
and then once every 6 months for 18 months. Adverse
events were graded for severity according to predeﬁned
criteria, and their relationships to the trial medications
were assessed.
Study end points
The primary end points were induction of remission at
6 months, and severe adverse events including death and
ESRD. As secondary end points, the effectiveness and
safety of the standard protocols, as well as health-related
quality of life (HRQOL), were evaluated. With regard to
the effectiveness, we evaluated time from initial treatment
to remission; time from remission to relapse, if any; relapse
rate; and VDI. With regard to safety and HRQOL, all
adverse events and SF-36 were evaluated.
Statistical analysis
Quantitative variables were compared using Student’s
t-test or the Mann–Whitney nonparametric test. Categorical
variables were compared using the v
2 test or Fisher’s exact
test. In all analyses, P\0.05 was taken to indicate sta-
tistical signiﬁcance. Kaplan–Meier analysis was used to
evaluate patient survival. SF-36 domain scores were cal-
culated using the norm-based scoring algorithm, in which
the scores were standardized to a mean of 50 and SD of 10
in the Japanese general population [13]. A one-sample
t-test was used to determine whether the SF-36 domain
scores of study subjects differed signiﬁcantly from the
Japanese general population norm. Repeated measures
analysis of variance was used to test for changes with time
in the SF-36 domain scores.
Results
Outcome of the study
Patients were enrolled in the study between July 2004 and
September 2006. As illustrated in Fig. 1, 52 patients were
screened, and 4 were excluded according to the criteria
described above. The remaining 48 patients received the
severity-based treatment: 2, 23, and 23 patients received
treatment for the most severe, severe, and mild forms,
respectively. One patient from the mild-form group was
lost to follow-up within 6 weeks, and therefore the study
population for further analysis consisted of the remaining
47 patients.
One patient in the severe-form group, with an RPGN
type, started hemodialysis on day 4 and developed ESRD.
Three patients died without remission, at 9 days,
2.5 months, and 3 months, respectively. At 6 months, 42
patients had achieved remission; 1, 20, and 21 of these
patients were from the most severe form, severe form, and
mild-form groups, respectively. One patient in the severe-
form group died after achieving remission, without relapse,
at 10 months. Eight patients showed relapse (3 and 5 from
the severe-form group and the mild-form group, respec-
tively). Among the relapsed patients, re-remission occurred
in7,whiletheremainingpatientfromthesevere-formgroup
diedofsepsisduetoopportunisticinfectionat11 months.At
the last observation, 32 patients had maintained remission
withoutdeathorrelapse;1inthemostsevere-formgroup,15
in the severe-form group, and 16 in the mild-form group.
Baseline characteristics of patients
Patients were further stratiﬁed based on their organ
involvement as described above. Table 1 shows the
Mod Rheumatol (2012) 22:394–404 397
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characteristics. One of the 2 patients in the most severe-
form group had a cerebral bleeding type, and the other had
resistant severe disease. No other types deﬁned above were
included in the most severe form group. RPGN type was
most frequent among the severe-form group. The mean age
of the patients was 66.6 years, and the majority of the
patients (all except for two patients) ranged in age between
56 and 79 years. The patients were predominantly female.
Males were more common in the severe-form group
(52.2%) and much less common in the mild-form group
(21.7%). In total, 75% of the patients showed renal
involvement, and 45.8% showed pulmonary involvement.
The mean BVAS new/worse of the 48 patients enrolled
in this study was 12.2 at baseline. The BVAS in the severe-
form group was signiﬁcantly higher than that in the mild-
form group (P\0.05). In the severe-form group, the
generalized type showed the highest BVAS, followed by
the pulmo-renal type, and the RPGN type.
The mean titer of MPO-ANCA at baseline was
423 EU/mL. The highest average titer was detected in the
severe-form group; in the patients in this group, the RPGN
Fig. 1 Outcomes of the patients
registered in the Japanese
patients with MPO-ANCA-
associated vasculitis (JMAAV)
trial. ESRD End-stage renal
disease
Table 1 Baseline characteristics of patients stratiﬁed by severity
Severity/Type n 
Age      
mean (range) 
Gender     
M/F (%Male) 
Renal 
involvement  
n (%) 
Pulmonary 
involvement   
n (%) 
BVAS    
mean (SD) 
MPO-ANCA 
(EU/mL)     
mean (SD) 
Serum creatinine 
(mg/dL)   
mean (SD) 
Most severe 2 66.5 (62-71) 0/2 (0) 2 (100) 2 (100) 11.5 (12.0) 406.5 (19.1) 3.70 (1.90) 
Severe 23 67.6 (56-76) 12/11 (52.2) 23 (100) 9 (30.1) 15.3 (9.0) 648.7 (1112.9) 3.33 (2.71) 
Mild 23 65.7 (26-79) 5/18 (21.7) 11 (47.8) 11 (47.8) 9.2 (8.2) 199.6 (169.4) 0.96 (0.67) 
Generalized  3 64.3 (57-74) 3/0 (100) 3 (100) 2 (66.7) 25.7 (7.2) 522.7 (78.2) 1.40 (0.53) 
Pulmo-renal  4 68.8 (56-75) 1/3 (25) 4 (100) 4 (100) 15.8 (5.7) 448.5 (353.0) 2.36 (2.15) 
RPGN  16 67.9 (56-76) 8/8 (50) 16 (100) 3 (18.8) 13.2 (13.2) 722.4 (1330.8) 3.93 (2.91) 
Renal-limited  4 59.3 (45-69) 1/3 (25) 4 (100) 0 14.3 (7.9) 164.2 (172.3) 1.78 (1.14) 
Pulmonary-limited  6 66.3 (57-75) 1/5 (16.7) 0 6 (100) 3.3 (3.1) 135.3 (94.0) 0.61 (0.18) 
Miscellaneous  13 67.4 (26-79) 3/10 (23.1) 7 (53.9) 5 (38.5) 10.3 (9.0) 240.2 (193.0) 0.87 (0.43) 
Total 48 66.6 (26-79) 17/31 (35.4) 36 (75) 22 (45.8) 12.2 (9.1) 423.4 (801.6) 2.20 (2.28) 
BVAS Birmingham vasculitis activity score, MPO-ANCA myeloperoxidase-anti-neutrophil cytoplasmic antibodies, RPGN rapidly progressive
glomerulonephritis, SD standard deviation
398 Mod Rheumatol (2012) 22:394–404
123type showed the highest average titer, followed by the
generalized type, and the pulmo-renal type. PR3-ANCA
was tested in 25 patients, all of whom showed negative
results.
The mean serum creatinine level at baseline was 2.2 mg/
dL. The highest average level was detected in the severe-
form group; in these patients, the RPGN type showed the
highest average level, followed by the pulmo-renal type,
and the generalized type.
Time courses of changes in BVAS, MPO-ANCA,
and serum creatinine
Figure 2a shows the time courses of changes in BVAS in the
severe- and mild-form groups in the present study popula-
tion. The scores declined rapidly during the ﬁrst 6 weeks.
However, even at 6 weeks, the mean BVAS in the severe-
form group was signiﬁcantly higher than that in the
mild-form group (P\0.05). The scores in the severe- and
mild-form groups were increased at 6 months and thereafter,
reﬂecting the 8 patients showing relapse described above. On
theotherhand,therewerenosigniﬁcantdifferencesinBVAS
scores for persistent disease between the baseline and any
other examination time points (data not shown). Among the
forms, however, the BVAS persistent scores in the severe-
form group were signiﬁcantly higher than those in the mild-
form group at all examination time points (data not shown).
Figure 2b shows the time courses of changes in the
MPO-ANCA titers in the severe- and mild-form groups. In
both forms, the titer declined quickly during the ﬁrst
6 weeks, and became negative at 9 months.
Figure 2c shows the time courses of changes in serum
creatinine levels in the severe- and mild-form groups. In
the severe-form group, the level decreased rapidly to
1.8 mg/dL during the ﬁrst 6 weeks, and remained relatively
constant thereafter. In contrast, the creatinine level in the
mild-form group remained within the normal range
throughout the observation period.
VDI
The mean ± SD VDI values at the baseline and at
18 months were 2.2 ± 2.1 (median 2, range 0–12) and
3.2 ± 2.9 (median 2, range 0–12), respectively. Compared
with VDI values in the CYCAZAREM trial [7], where the
mean VDI (95% conﬁdence interval) values at baseline and
at 18 months were 1.3 (1.0–1.6) and 2.5 (2.1–3.0),
respectively, those in the present trial were higher by 0.9
and 0.7, respectively.
Both the baseline VDI and the VDI at 18 months were
signiﬁcantly higher in the severe-form group than in the
mild-form group (P = 0.004 for baseline and P = 0.001
for 18 months). The baseline VDI in patients with
remission (n = 42) was 1.71 ± 1.55, which was signiﬁ-
cantly lower than that in patients without remission
(n = 5), 2.61 ± 1.52 (P\0.001).
The correlation between VDI and BVAS was studied.
Patients with baseline BVAS persistent of C4( n = 22)
showed a signiﬁcantly higher VDI (4.32 ± 3.70) at
18 months than those with BVAS persistent of \4
(n = 25), in whom VDI was 2.29 ± 1.61 at 18 months
(P = 0.024). However, there was no signiﬁcant correlation
Fig. 2 Time courses of changes in the Birmingham vasculitis activity
score (BVAS), myeloperoxidase-anti-neutrophil cytoplasmic antibod-
ies (MPO-ANCA) titer, and serum creatinine. The mean values of
a BVAS, b ANCA titers, and c serum creatinine in each group
stratiﬁed according to severity are plotted at 6 weeks, 3 months,
6 months, 9 months, 12 months, 15 months, and 18 months. Open
squares/solid lines and closed circles/dotted lines indicate severe- and
mild-form groups, respectively. The data for the most severe-form
group were omitted from the ﬁgure as this group included only a
single patient
Mod Rheumatol (2012) 22:394–404 399
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Therefore, the baseline value of BVAS persistent seemed
to be important for indicating organ damage during the
course of treatment of AVV.
SF-36
Of the 48 patients enrolled in the study, 32 had completed
the SF-36 questionnaire at baseline. The mean norm-based
scores for SF-36 domains at baseline were signiﬁcantly
lower than the Japanese general population norm. The
lowest value (mean ± SD) was found in physical func-
tioning (27.3 ± 18.9), followed by role physical
(31.5 ± 15.3), role emotional (37.4 ± 15.3), social func-
tioning (39.0 ± 13.8), general health (41.5 ± 10.5), and
mental health (43.9 ± 11.2). Patients with remission
showed signiﬁcant improvements in all SF-36 domains,
except for general health and role emotional. The physical
components had improved signiﬁcantly but remained
considerably impaired at the 18-month follow-up, whereas
the mental components approximated to the Japanese
general population norm by 6 months.
Remission
As described above, 42 patients achieved remission. As
illustrated in Fig. 3a, the majority of patients (n = 36) had
achieved remission by the ﬁrst 6 weeks, followed by 6
patients within 3 months, and the last patient by 6 months.
The overall remission induction rate was 89.4% (42/47).
Table 2 presents a summary of the remission induction
therapy employed in each form/type of patient. All patients
received oral prednisolone, with a mean initial dose of
37.5 mg/day. The highest and lowest mean initial doses
were observed in the generalized type of the severe form
and the pulmonary-limited type of the mild form, respec-
tively. Sixteen patients received only glucocorticoid with-
out any immunosuppressive agents (7 of 23 patients in the
severe-form group and 9 of 23 patients in the mild-form
group). Six of 16 patients with the RPGN type and 3 of 6
patients with the pulmonary-limited type received no
additional immunosuppressive agents.
Death and ESRD
A total of 5 patients died in this prospective study. As
shown in Fig. 3b, death occurred at 9 days, 2.5 months,
3 months, 10 months, and 11 months after the start of the
treatment in these 5 patients. Of the 5 deaths, only one was
considered to be disease-associated; this death occurred on
day 9 in a patient with the most severe form, cerebral
bleeding type, despite intensive treatment including high-
dose glucocorticoid and intravenous cyclophosphamide,
but no plasmapheresis. In the 4 remaining patients who
died the disease was the severe form in 3 and mild form in
1. Two patients died after remission: one due to opportu-
nistic infection, and the other due to pulmonary failure,
presumably associated with Pneumocystis jirovecii pneu-
monia (PCP). The remaining two patients died without
remission, at 2.5 and 3 months: one due to cerebral hem-
orrhage as an atherosclerotic event and the other due to
interstitial lung disease of undetermined origin. In this trial,
Fig. 3 Kaplan-Meier estimates of time to remission induction,
survival, and relapse. a Time to remission induction within 6 months
after the start of treatment. The vertical axis indicates the percentage
of patients with remission among 47 patients receiving predeﬁned
treatment protocols. b Survival during the 18-month observation
period. The vertical axis indicates the percentage of patients who
survived among 47 patients receiving predeﬁned treatment protocols.
c Time from remission to relapse. The vertical axis indicates the
percentage of relapse-free patients among 42 patients who achieved
remission. The horizontal axes indicate time from the start of
treatment in a and b, and time from remission in c
400 Mod Rheumatol (2012) 22:394–404
123one patient with severe form, RPGN type, underwent he-
modialysis on day 4 and developed ESRD despite high-
dose glucocorticoid therapy.
Relapse
Table 3 shows the remission-maintenance therapy admin-
istered in the 42 patients after achieving remission. Thirty
patients (71.4%) received only glucocorticoid, and the
remaining 12 patients also received immunosuppressive
agents: 5 patients received intravenous cyclophosphamide
and 5 received azathioprine. Relapse occurred in 8 of the
42 patients (relapse rate = 19.0%); relapse occurred in 3 of
20 patients with the severe form (relapse rate = 15.0%),
but 5 cases of relapse occurred among the 21 patients with
the mild form (relapse rate = 23.8%). Of the latter 5
relapses, 4 occurred in 17 patients who received no
immunosuppressant. As shown in Fig. 3c, all relapses
occurred between 12 and 30 weeks after the induction of
remission. The relapse group had signiﬁcantly higher
BVAS new/worse values at 6 months than the non-relapse
group (3.75 ± 5.78 vs. 0.125 ± 0.554, respectively;
P = 0.0001). However, there was no signiﬁcant difference
in BVAS persistent values between the relapse and non-
relapse groups (3.75 ± 3.73 vs. 3.34 ± 2.72, respectively).
There were no signiﬁcant differences in several serological
markers, such as CRP and ANCA titers, between the
relapse and non-relapse groups (data not shown).
Adverse events
During the 18-month observation period, 29 events of
infection of grade 3 or higher were observed. Among these,
bacterial infection was noted in 11 events (10 patients): 8
events were grade 3, 2 were grade 4, and the remaining 1
was grade 5. Fungal infection was observed in 6 events
(5 patients): 3 cases of aspergillosis and 3 cases of candi-
diasis (1 patient developed both aspergillosis and
Table 2 Remission induction
therapy
mPSL Methylprednisolone,
IVCY intravenous
cyclophosphamide, POCY oral
cyclophosphamide, AZA
azathioprine, MTX
methotrexate, PE plasma
exchange, PSL prednisolone
Severity/Type n
mPSL 
Pulse
Oral PSL plus  Mean
PSL
(mg/day) (-) IVCY POCY AZA MTX PE
Most severe 2202 00 01 5 0
Severe 23 13 7 15 1 0 0 1 41 
Generalized 
Pulmo-renal 
RPGN
Mild 23 4 10 7 3 2 1 0 33
Renal-limited 
Pulmonary-limited 
Miscellaneous 
3203 00 00 5 5
4213 00 00 3 9
16 9 6 9 1 0 0 1 38
4322 00 00 4 6
6031 10 10 2 7
13 1 5 4 2 2 0 0 37
Total 48 19 17 24 4 2 1 2 37.5 
Table 3 Remission
maintenance therapy
Numbers in parentheses indicate
numbers of relapsed patients
IVCY Intravenous
cyclophosphamide, AZA
azathioprine, MZB mizoribin,
TAC tacrolimus
Severity/Type Total(*) 
Oral prednisolone plus(*) 
None IVCY AZA MZB TAC
Most severe 1(0) 0 1(0) 0 0 0
Severe 20(3) 14(2) 1(0) 4(1) 1(0) 0 
Generalized
Pulmo-renal
RPGN
3(1) 0 0 3(1) 0 0
3(0) 3(0) 0 0 00
14(2) 11(2) 1(0) 1(0) 1(0) 0
Mild 21(5) 16(3) 3(1) 1(0) 0 1(1) 
Pulmonary-limited 6(3) 4(1) 1(1) 0 0 1(1)
Renal-limited 3(1) 3(1) 0 0 00
Miscellaneous 12(1) 9(1) 2(0) 1(0) 0 0
Total 42(8) 30(5) 5(1) 5(1) 1(0) 1(1)
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123candidiasis). Of these 6 events, 3 were associated with
aspergillus pneumonia without prophylactic antifungal
agents. In total, however, fungal infection was observed in
1 of 13 patients with prophylaxis and 4 of 35 without
prophylaxis (no signiﬁcant difference, P[0.05).
There were 7 viral infection events (in 7 patients): 4
with varicella-zoster virus (VZV), 2 with cytomegalovirus
(CMV) (1 encephalitis and 1 positive antigenemia), and 1
with hepatitis C virus (HCV) (the hepatitis occurred in an
HCV carrier). All patients with VZV developed herpes
zoster and one patient with CMV developed encephalitis
while receiving cyclophosphamide.
There were 3 PCP events (in 3 patients). Of the 48
patients enrolled in this study, 31 received prophylactic
trimethoprim-sulfamethoxazole (TMP-SMX), while the
remaining 17 did not. Two patients with PCP did not
receive prophylaxis, and the other patient developed PCP
2 months after prophylaxis was stopped due to liver dam-
age. Thus, no patients who received prophylaxis developed
PCP.
Other adverse events included diabetes mellitus (9
events), bone fracture (3 events), cerebral vascular events
(3 events), and cardiac vascular event (1 event). Two of the
cerebral vascular events were of grade 5.
Discussion
We performed a prospective, open-label, multicenter trial
(JMAAV) to evaluate the usefulness of a severity-based
regimen for Japanese patients with MPO-ANCA-associated
vasculitis. In this trial, patients were stratiﬁed into 3 severity
groups and 12 disease types, and then received predeter-
mined severity- and type-based protocols. These protocols
were designed to choose an appropriate treatment regimen
and to promote prediction of the outcome for each patient.
The rates of remission, death, ESRD, and relapse obtained
in the trial were comparable to those reported previously in
European RCTs [7, 8] with minor differences. Thus, tailor-
made treatment based on patients’ disease severity and
disease type seemed to be useful in determining treatment
regimens. The validity of the stratiﬁcation we used, how-
ever, is also a matter of investigation in that it is related to
other severity-based classiﬁcations, such as the ﬁve-factor
score used by the French study group [14, 15].
Another ﬁnding of this trial was the concept of pul-
monary-limited vasculitis. To date, the only organ-limited
ANCA-associated vasculitis has been renal-limited vascu-
litis [16]. Six patients with only pulmonary involvement
were included in the JMAAV trial. These patients were
positive for MPO-ANCA, and showed interstitial lung
disease without other major organ involvement. It may be
possible to designate this type as pulmonary-limited
vasculitis, another type of organ-limited vasculitis. As
renal-limited vasculitis includes a wide spectrum of renal
damage, from mild glomerulonephritis to RPGN, pul-
monary-limited vasculitis may also include pulmonary
lesions of varying severity. Further prospective studies are
required to clarify these points.
Recently, the British Society of Rheumatology (BSR)/
British Health Professionals in Rheumatology (BHPR) and
the European League Against Rheumatism (EULAR)
issued guidelines and recommendations, respectively,
dividing patients with ANCA-associated vasculitis into 3
(localized/early systemic, generalized, and severe) [17] and
5 categories (localized, early systemic, generalized, severe,
and refractory) [18], respectively, and recommended cate-
gory-based treatment. These recommendations were based
on several RCTs dealing with large numbers of patients
with WG, and therefore caution is required in applying
them to Japanese patients with MPO-ANCA-associated
vasculitis. However, these recommendations also referred
to precise dose reduction of cyclophosphamide and
adjunctive therapy including prophylaxis against opportu-
nistic infections, which must also be considered in the
treatment of Japanese patients.
In our trial, two cases of grade 4 and 1 case of grade 5
infection (death) were observed as treatment-related severe
infections. All of these patients showed urinary tract
infection by Escherichia coli, which occurred during
remission-maintenance treatment with glucocorticoid and
cyclophosphamide. Oral cyclophosphamide or azathioprine
was indicated as an immunosuppressive agent during
remission maintenance in the JMAAV protocol, but the
agents were employed at the discretion of the attending
physician. As the CYCAZAREM, WEGENT (Wegener’s
granulomatosis-entretien trial) [19], and IMPROVE
(international mycophenolate protocol to reduce outbreaks
of vasculitides randomized trial) trials [20] have indicated
that azathioprine is the best adjunctive immunosuppressant
during maintenance treatment, the use of this agent for
MPA patients should be analyzed in future trials. In addi-
tion, a tapering protocol was not determined in the JMAAV
trial, and therefore the total amounts of glucocorticoid
administered were greater than those outlined in the
European recommendations (data not shown). This greater
amount seemed to be associated with several glucocorti-
coid-associated adverse events, including infection.
Prophylaxis is another countermeasure to cope with
opportunistic infection. In the JMAAV trial, prophylactic
protocols such as the use of TMP-SMX for PCP and the use
of antifungal agents for fungal infection were not precisely
determined. Three patients without prophylaxis suffered
from PCP, whereas there were no cases of PCP among
patients with prophylactic TMP-SMX. This result indicated
that TMP-SMX should be recommended to prevent PCP in
402 Mod Rheumatol (2012) 22:394–404
123future trials in Japan. Although there were no signiﬁcant
differences in the incidences of fungal infection between
those who received and those who did not receive pro-
phylactic antifungal agents, patients at high risk of severe
pulmonary fungal infection should receive prophylactic
antifungal agents.
The relapse rate in the JMAAV trial was 19%, which
was higher than that in the MPA subgroup (8%) and as
high as that in the WG subgroup (18%) in the CYCAZA-
REM trial [7]. In our trial, the relapse rate was highest in
patients with the mild form, especially in those with the
pulmonary-limited type (3 cases of relapse in 6 patients),
followed by those with the renal-limited type (1 relapse in
3 patients). Although all patients in the CYCAZAREM
trial were treated with oral cyclophosphamide as well as
glucocorticoid to induce remission, the use of cyclophos-
phamide was not obligatory in our trial, especially in our
regimen for patients in the mild-form group. This may
explain the differences in relapse rates between the trials.
Further prospective studies are required to evaluate whe-
ther cyclophosphamide and azathioprine may be essential
for the induction and maintenance of remission, respec-
tively, for a certain population of patients in the mild-form
group.
Health-related quality of life (HRQOL) in our trial
showed considerable deterioration in patients with MPO-
ANCA-associated vasculitis before treatment. During
18 months of follow-up, there were signiﬁcant improve-
ments in all SF-36 domains, except for general health and
role emotional, in patients who achieved and sustained
remission during the follow-up period. Therefore, the
development of more effective treatment strategies for
MPO-ANCA-associated vasculitis may be required to
achieve better HRQOL.
In conclusion, the ﬁrst prospective trial for Japanese
patients with MPO-ANCA-associated vasculitis, the
JMAAV trial, revealed the usefulness of severity-based
treatment, and indicated the possible disease entity of
‘‘pulmonary-limited vasculitis’’ as a type of organ-limited
ANCA-associated vasculitis. To achieve better outcomes,
we propose several points to improve the treatment pro-
tocol: i.e., a glucocorticoid-tapering protocol, the use of
less toxic immunosuppressants such as azathioprine in
remission-maintenance therapy, and intensive prophylaxis
for PCP or profound fungal infection.
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